nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP4A11—Cisplatin—testicular cancer	0.153	0.201	CbGbCtD
Lansoprazole—CYP2C18—Ifosfamide—testicular cancer	0.138	0.181	CbGbCtD
Lansoprazole—ABCG2—Dactinomycin—testicular cancer	0.0526	0.0691	CbGbCtD
Lansoprazole—CYP1B1—Doxorubicin—testicular cancer	0.0426	0.056	CbGbCtD
Lansoprazole—ABCG2—Carboplatin—testicular cancer	0.0353	0.0465	CbGbCtD
Lansoprazole—CYP2C8—Ifosfamide—testicular cancer	0.0331	0.0435	CbGbCtD
Lansoprazole—ABCG2—Cisplatin—testicular cancer	0.0302	0.0397	CbGbCtD
Lansoprazole—ABCG2—Etoposide—testicular cancer	0.0297	0.039	CbGbCtD
Lansoprazole—CYP2C19—Ifosfamide—testicular cancer	0.0277	0.0365	CbGbCtD
Lansoprazole—CYP2C9—Ifosfamide—testicular cancer	0.0231	0.0303	CbGbCtD
Lansoprazole—ABCG2—Doxorubicin—testicular cancer	0.0202	0.0266	CbGbCtD
Lansoprazole—ABCG2—Methotrexate—testicular cancer	0.0196	0.0258	CbGbCtD
Lansoprazole—ABCB1—Dactinomycin—testicular cancer	0.0189	0.0249	CbGbCtD
Lansoprazole—CYP2C8—Etoposide—testicular cancer	0.0158	0.0208	CbGbCtD
Lansoprazole—CYP3A4—Ifosfamide—testicular cancer	0.0134	0.0176	CbGbCtD
Lansoprazole—CYP1A2—Etoposide—testicular cancer	0.0122	0.0161	CbGbCtD
Lansoprazole—ABCB1—Vinblastine—testicular cancer	0.0119	0.0156	CbGbCtD
Lansoprazole—CYP2C9—Cisplatin—testicular cancer	0.0112	0.0147	CbGbCtD
Lansoprazole—CYP2D6—Vinblastine—testicular cancer	0.0112	0.0147	CbGbCtD
Lansoprazole—ABCB1—Cisplatin—testicular cancer	0.0109	0.0143	CbGbCtD
Lansoprazole—ABCB1—Etoposide—testicular cancer	0.0107	0.0141	CbGbCtD
Lansoprazole—ABCB1—Doxorubicin—testicular cancer	0.00729	0.00959	CbGbCtD
Lansoprazole—CYP3A4—Vinblastine—testicular cancer	0.00711	0.00935	CbGbCtD
Lansoprazole—ABCB1—Methotrexate—testicular cancer	0.00707	0.00929	CbGbCtD
Lansoprazole—CYP2D6—Doxorubicin—testicular cancer	0.00687	0.00904	CbGbCtD
Lansoprazole—CYP3A4—Etoposide—testicular cancer	0.00641	0.00843	CbGbCtD
Lansoprazole—CYP3A4—Doxorubicin—testicular cancer	0.00437	0.00575	CbGbCtD
Lansoprazole—Pharyngitis—Epirubicin—testicular cancer	9.26e-05	0.000387	CcSEcCtD
Lansoprazole—Cardiac disorder—Methotrexate—testicular cancer	9.26e-05	0.000386	CcSEcCtD
Lansoprazole—Sweating—Doxorubicin—testicular cancer	9.22e-05	0.000385	CcSEcCtD
Lansoprazole—Urinary tract disorder—Epirubicin—testicular cancer	9.22e-05	0.000385	CcSEcCtD
Lansoprazole—Oedema peripheral—Epirubicin—testicular cancer	9.19e-05	0.000384	CcSEcCtD
Lansoprazole—Haematuria—Doxorubicin—testicular cancer	9.17e-05	0.000383	CcSEcCtD
Lansoprazole—Connective tissue disorder—Epirubicin—testicular cancer	9.17e-05	0.000383	CcSEcCtD
Lansoprazole—Urethral disorder—Epirubicin—testicular cancer	9.15e-05	0.000382	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Doxorubicin—testicular cancer	9.1e-05	0.00038	CcSEcCtD
Lansoprazole—Epistaxis—Doxorubicin—testicular cancer	9.07e-05	0.000379	CcSEcCtD
Lansoprazole—Angiopathy—Methotrexate—testicular cancer	9.05e-05	0.000378	CcSEcCtD
Lansoprazole—Sinusitis—Doxorubicin—testicular cancer	9.03e-05	0.000377	CcSEcCtD
Lansoprazole—Immune system disorder—Methotrexate—testicular cancer	9.01e-05	0.000376	CcSEcCtD
Lansoprazole—Visual impairment—Epirubicin—testicular cancer	8.99e-05	0.000375	CcSEcCtD
Lansoprazole—Mediastinal disorder—Methotrexate—testicular cancer	8.99e-05	0.000375	CcSEcCtD
Lansoprazole—Agranulocytosis—Doxorubicin—testicular cancer	8.98e-05	0.000375	CcSEcCtD
Lansoprazole—Chills—Methotrexate—testicular cancer	8.95e-05	0.000373	CcSEcCtD
Lansoprazole—Nausea—Ifosfamide—testicular cancer	8.9e-05	0.000371	CcSEcCtD
Lansoprazole—Diarrhoea—Cisplatin—testicular cancer	8.83e-05	0.000369	CcSEcCtD
Lansoprazole—Erythema multiforme—Epirubicin—testicular cancer	8.82e-05	0.000368	CcSEcCtD
Lansoprazole—Alopecia—Methotrexate—testicular cancer	8.81e-05	0.000368	CcSEcCtD
Lansoprazole—Bradycardia—Doxorubicin—testicular cancer	8.79e-05	0.000367	CcSEcCtD
Lansoprazole—Mental disorder—Methotrexate—testicular cancer	8.74e-05	0.000365	CcSEcCtD
Lansoprazole—Eye disorder—Epirubicin—testicular cancer	8.72e-05	0.000364	CcSEcCtD
Lansoprazole—Hypersensitivity—Etoposide—testicular cancer	8.72e-05	0.000364	CcSEcCtD
Lansoprazole—Tinnitus—Epirubicin—testicular cancer	8.7e-05	0.000363	CcSEcCtD
Lansoprazole—Erythema—Methotrexate—testicular cancer	8.68e-05	0.000362	CcSEcCtD
Lansoprazole—Malnutrition—Methotrexate—testicular cancer	8.68e-05	0.000362	CcSEcCtD
Lansoprazole—Cardiac disorder—Epirubicin—testicular cancer	8.66e-05	0.000362	CcSEcCtD
Lansoprazole—Rhinitis—Doxorubicin—testicular cancer	8.66e-05	0.000361	CcSEcCtD
Lansoprazole—Hepatitis—Doxorubicin—testicular cancer	8.64e-05	0.00036	CcSEcCtD
Lansoprazole—Hypoaesthesia—Doxorubicin—testicular cancer	8.59e-05	0.000359	CcSEcCtD
Lansoprazole—Pharyngitis—Doxorubicin—testicular cancer	8.57e-05	0.000358	CcSEcCtD
Lansoprazole—Urinary tract disorder—Doxorubicin—testicular cancer	8.53e-05	0.000356	CcSEcCtD
Lansoprazole—Oedema peripheral—Doxorubicin—testicular cancer	8.51e-05	0.000355	CcSEcCtD
Lansoprazole—Dysgeusia—Methotrexate—testicular cancer	8.5e-05	0.000355	CcSEcCtD
Lansoprazole—Asthenia—Etoposide—testicular cancer	8.49e-05	0.000354	CcSEcCtD
Lansoprazole—Connective tissue disorder—Doxorubicin—testicular cancer	8.49e-05	0.000354	CcSEcCtD
Lansoprazole—Angiopathy—Epirubicin—testicular cancer	8.47e-05	0.000353	CcSEcCtD
Lansoprazole—Urethral disorder—Doxorubicin—testicular cancer	8.47e-05	0.000353	CcSEcCtD
Lansoprazole—Immune system disorder—Epirubicin—testicular cancer	8.43e-05	0.000352	CcSEcCtD
Lansoprazole—Mediastinal disorder—Epirubicin—testicular cancer	8.41e-05	0.000351	CcSEcCtD
Lansoprazole—Back pain—Methotrexate—testicular cancer	8.4e-05	0.00035	CcSEcCtD
Lansoprazole—Chills—Epirubicin—testicular cancer	8.37e-05	0.00035	CcSEcCtD
Lansoprazole—Pruritus—Etoposide—testicular cancer	8.37e-05	0.000349	CcSEcCtD
Lansoprazole—Arrhythmia—Epirubicin—testicular cancer	8.34e-05	0.000348	CcSEcCtD
Lansoprazole—Visual impairment—Doxorubicin—testicular cancer	8.32e-05	0.000347	CcSEcCtD
Lansoprazole—Alopecia—Epirubicin—testicular cancer	8.25e-05	0.000344	CcSEcCtD
Lansoprazole—Vomiting—Cisplatin—testicular cancer	8.21e-05	0.000343	CcSEcCtD
Lansoprazole—Vision blurred—Methotrexate—testicular cancer	8.18e-05	0.000341	CcSEcCtD
Lansoprazole—Mental disorder—Epirubicin—testicular cancer	8.18e-05	0.000341	CcSEcCtD
Lansoprazole—Erythema multiforme—Doxorubicin—testicular cancer	8.17e-05	0.000341	CcSEcCtD
Lansoprazole—Rash—Cisplatin—testicular cancer	8.14e-05	0.00034	CcSEcCtD
Lansoprazole—Dermatitis—Cisplatin—testicular cancer	8.13e-05	0.000339	CcSEcCtD
Lansoprazole—Erythema—Epirubicin—testicular cancer	8.12e-05	0.000339	CcSEcCtD
Lansoprazole—Malnutrition—Epirubicin—testicular cancer	8.12e-05	0.000339	CcSEcCtD
Lansoprazole—Diarrhoea—Etoposide—testicular cancer	8.09e-05	0.000338	CcSEcCtD
Lansoprazole—Eye disorder—Doxorubicin—testicular cancer	8.07e-05	0.000337	CcSEcCtD
Lansoprazole—Ill-defined disorder—Methotrexate—testicular cancer	8.06e-05	0.000336	CcSEcCtD
Lansoprazole—Tinnitus—Doxorubicin—testicular cancer	8.05e-05	0.000336	CcSEcCtD
Lansoprazole—Anaemia—Methotrexate—testicular cancer	8.02e-05	0.000335	CcSEcCtD
Lansoprazole—Cardiac disorder—Doxorubicin—testicular cancer	8.01e-05	0.000335	CcSEcCtD
Lansoprazole—Flatulence—Epirubicin—testicular cancer	8.01e-05	0.000334	CcSEcCtD
Lansoprazole—Tension—Epirubicin—testicular cancer	7.97e-05	0.000333	CcSEcCtD
Lansoprazole—Dysgeusia—Epirubicin—testicular cancer	7.96e-05	0.000332	CcSEcCtD
Lansoprazole—Nervousness—Epirubicin—testicular cancer	7.89e-05	0.000329	CcSEcCtD
Lansoprazole—Back pain—Epirubicin—testicular cancer	7.86e-05	0.000328	CcSEcCtD
Lansoprazole—Angiopathy—Doxorubicin—testicular cancer	7.84e-05	0.000327	CcSEcCtD
Lansoprazole—Malaise—Methotrexate—testicular cancer	7.83e-05	0.000327	CcSEcCtD
Lansoprazole—Dizziness—Etoposide—testicular cancer	7.82e-05	0.000326	CcSEcCtD
Lansoprazole—Muscle spasms—Epirubicin—testicular cancer	7.81e-05	0.000326	CcSEcCtD
Lansoprazole—Immune system disorder—Doxorubicin—testicular cancer	7.8e-05	0.000326	CcSEcCtD
Lansoprazole—Vertigo—Methotrexate—testicular cancer	7.8e-05	0.000326	CcSEcCtD
Lansoprazole—Mediastinal disorder—Doxorubicin—testicular cancer	7.78e-05	0.000325	CcSEcCtD
Lansoprazole—Leukopenia—Methotrexate—testicular cancer	7.77e-05	0.000324	CcSEcCtD
Lansoprazole—Chills—Doxorubicin—testicular cancer	7.75e-05	0.000323	CcSEcCtD
Lansoprazole—Arrhythmia—Doxorubicin—testicular cancer	7.71e-05	0.000322	CcSEcCtD
Lansoprazole—Nausea—Cisplatin—testicular cancer	7.67e-05	0.00032	CcSEcCtD
Lansoprazole—Vision blurred—Epirubicin—testicular cancer	7.66e-05	0.00032	CcSEcCtD
Lansoprazole—Alopecia—Doxorubicin—testicular cancer	7.63e-05	0.000318	CcSEcCtD
Lansoprazole—Cough—Methotrexate—testicular cancer	7.58e-05	0.000316	CcSEcCtD
Lansoprazole—Mental disorder—Doxorubicin—testicular cancer	7.57e-05	0.000316	CcSEcCtD
Lansoprazole—Ill-defined disorder—Epirubicin—testicular cancer	7.54e-05	0.000315	CcSEcCtD
Lansoprazole—Convulsion—Methotrexate—testicular cancer	7.52e-05	0.000314	CcSEcCtD
Lansoprazole—Vomiting—Etoposide—testicular cancer	7.52e-05	0.000314	CcSEcCtD
Lansoprazole—Erythema—Doxorubicin—testicular cancer	7.52e-05	0.000314	CcSEcCtD
Lansoprazole—Malnutrition—Doxorubicin—testicular cancer	7.52e-05	0.000314	CcSEcCtD
Lansoprazole—Anaemia—Epirubicin—testicular cancer	7.51e-05	0.000313	CcSEcCtD
Lansoprazole—Agitation—Epirubicin—testicular cancer	7.47e-05	0.000312	CcSEcCtD
Lansoprazole—Rash—Etoposide—testicular cancer	7.46e-05	0.000311	CcSEcCtD
Lansoprazole—Dermatitis—Etoposide—testicular cancer	7.45e-05	0.000311	CcSEcCtD
Lansoprazole—Headache—Etoposide—testicular cancer	7.41e-05	0.000309	CcSEcCtD
Lansoprazole—Flatulence—Doxorubicin—testicular cancer	7.41e-05	0.000309	CcSEcCtD
Lansoprazole—Chest pain—Methotrexate—testicular cancer	7.39e-05	0.000308	CcSEcCtD
Lansoprazole—Myalgia—Methotrexate—testicular cancer	7.39e-05	0.000308	CcSEcCtD
Lansoprazole—Arthralgia—Methotrexate—testicular cancer	7.39e-05	0.000308	CcSEcCtD
Lansoprazole—Tension—Doxorubicin—testicular cancer	7.38e-05	0.000308	CcSEcCtD
Lansoprazole—Dysgeusia—Doxorubicin—testicular cancer	7.36e-05	0.000307	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	7.34e-05	0.000306	CcSEcCtD
Lansoprazole—Malaise—Epirubicin—testicular cancer	7.33e-05	0.000306	CcSEcCtD
Lansoprazole—Discomfort—Methotrexate—testicular cancer	7.3e-05	0.000305	CcSEcCtD
Lansoprazole—Nervousness—Doxorubicin—testicular cancer	7.3e-05	0.000305	CcSEcCtD
Lansoprazole—Vertigo—Epirubicin—testicular cancer	7.3e-05	0.000305	CcSEcCtD
Lansoprazole—Syncope—Epirubicin—testicular cancer	7.29e-05	0.000304	CcSEcCtD
Lansoprazole—Leukopenia—Epirubicin—testicular cancer	7.27e-05	0.000304	CcSEcCtD
Lansoprazole—Back pain—Doxorubicin—testicular cancer	7.27e-05	0.000303	CcSEcCtD
Lansoprazole—Muscle spasms—Doxorubicin—testicular cancer	7.23e-05	0.000302	CcSEcCtD
Lansoprazole—Palpitations—Epirubicin—testicular cancer	7.18e-05	0.0003	CcSEcCtD
Lansoprazole—Confusional state—Methotrexate—testicular cancer	7.14e-05	0.000298	CcSEcCtD
Lansoprazole—Loss of consciousness—Epirubicin—testicular cancer	7.14e-05	0.000298	CcSEcCtD
Lansoprazole—Cough—Epirubicin—testicular cancer	7.09e-05	0.000296	CcSEcCtD
Lansoprazole—Anaphylactic shock—Methotrexate—testicular cancer	7.09e-05	0.000296	CcSEcCtD
Lansoprazole—Vision blurred—Doxorubicin—testicular cancer	7.09e-05	0.000296	CcSEcCtD
Lansoprazole—Convulsion—Epirubicin—testicular cancer	7.04e-05	0.000294	CcSEcCtD
Lansoprazole—Infection—Methotrexate—testicular cancer	7.04e-05	0.000294	CcSEcCtD
Lansoprazole—Nausea—Etoposide—testicular cancer	7.03e-05	0.000293	CcSEcCtD
Lansoprazole—Hypertension—Epirubicin—testicular cancer	7.01e-05	0.000293	CcSEcCtD
Lansoprazole—Ill-defined disorder—Doxorubicin—testicular cancer	6.98e-05	0.000291	CcSEcCtD
Lansoprazole—Nervous system disorder—Methotrexate—testicular cancer	6.95e-05	0.00029	CcSEcCtD
Lansoprazole—Anaemia—Doxorubicin—testicular cancer	6.95e-05	0.00029	CcSEcCtD
Lansoprazole—Thrombocytopenia—Methotrexate—testicular cancer	6.94e-05	0.00029	CcSEcCtD
Lansoprazole—Chest pain—Epirubicin—testicular cancer	6.92e-05	0.000289	CcSEcCtD
Lansoprazole—Myalgia—Epirubicin—testicular cancer	6.92e-05	0.000289	CcSEcCtD
Lansoprazole—Arthralgia—Epirubicin—testicular cancer	6.92e-05	0.000289	CcSEcCtD
Lansoprazole—Agitation—Doxorubicin—testicular cancer	6.91e-05	0.000288	CcSEcCtD
Lansoprazole—Anxiety—Epirubicin—testicular cancer	6.89e-05	0.000288	CcSEcCtD
Lansoprazole—Skin disorder—Methotrexate—testicular cancer	6.88e-05	0.000287	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	6.87e-05	0.000287	CcSEcCtD
Lansoprazole—Hyperhidrosis—Methotrexate—testicular cancer	6.85e-05	0.000286	CcSEcCtD
Lansoprazole—Discomfort—Epirubicin—testicular cancer	6.83e-05	0.000285	CcSEcCtD
Lansoprazole—Malaise—Doxorubicin—testicular cancer	6.78e-05	0.000283	CcSEcCtD
Lansoprazole—Dry mouth—Epirubicin—testicular cancer	6.77e-05	0.000282	CcSEcCtD
Lansoprazole—Vertigo—Doxorubicin—testicular cancer	6.75e-05	0.000282	CcSEcCtD
Lansoprazole—Anorexia—Methotrexate—testicular cancer	6.75e-05	0.000282	CcSEcCtD
Lansoprazole—Syncope—Doxorubicin—testicular cancer	6.74e-05	0.000281	CcSEcCtD
Lansoprazole—Leukopenia—Doxorubicin—testicular cancer	6.73e-05	0.000281	CcSEcCtD
Lansoprazole—Confusional state—Epirubicin—testicular cancer	6.69e-05	0.000279	CcSEcCtD
Lansoprazole—Palpitations—Doxorubicin—testicular cancer	6.64e-05	0.000277	CcSEcCtD
Lansoprazole—Oedema—Epirubicin—testicular cancer	6.63e-05	0.000277	CcSEcCtD
Lansoprazole—Anaphylactic shock—Epirubicin—testicular cancer	6.63e-05	0.000277	CcSEcCtD
Lansoprazole—Hypotension—Methotrexate—testicular cancer	6.62e-05	0.000276	CcSEcCtD
Lansoprazole—Loss of consciousness—Doxorubicin—testicular cancer	6.61e-05	0.000276	CcSEcCtD
Lansoprazole—Infection—Epirubicin—testicular cancer	6.59e-05	0.000275	CcSEcCtD
Lansoprazole—Cough—Doxorubicin—testicular cancer	6.56e-05	0.000274	CcSEcCtD
Lansoprazole—Shock—Epirubicin—testicular cancer	6.52e-05	0.000272	CcSEcCtD
Lansoprazole—Convulsion—Doxorubicin—testicular cancer	6.51e-05	0.000272	CcSEcCtD
Lansoprazole—Nervous system disorder—Epirubicin—testicular cancer	6.5e-05	0.000271	CcSEcCtD
Lansoprazole—Thrombocytopenia—Epirubicin—testicular cancer	6.49e-05	0.000271	CcSEcCtD
Lansoprazole—Hypertension—Doxorubicin—testicular cancer	6.49e-05	0.000271	CcSEcCtD
Lansoprazole—Tachycardia—Epirubicin—testicular cancer	6.47e-05	0.00027	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Methotrexate—testicular cancer	6.46e-05	0.000269	CcSEcCtD
Lansoprazole—Skin disorder—Epirubicin—testicular cancer	6.44e-05	0.000269	CcSEcCtD
Lansoprazole—Hyperhidrosis—Epirubicin—testicular cancer	6.41e-05	0.000268	CcSEcCtD
Lansoprazole—Insomnia—Methotrexate—testicular cancer	6.41e-05	0.000267	CcSEcCtD
Lansoprazole—Chest pain—Doxorubicin—testicular cancer	6.4e-05	0.000267	CcSEcCtD
Lansoprazole—Myalgia—Doxorubicin—testicular cancer	6.4e-05	0.000267	CcSEcCtD
Lansoprazole—Arthralgia—Doxorubicin—testicular cancer	6.4e-05	0.000267	CcSEcCtD
Lansoprazole—Anxiety—Doxorubicin—testicular cancer	6.38e-05	0.000266	CcSEcCtD
Lansoprazole—Paraesthesia—Methotrexate—testicular cancer	6.36e-05	0.000266	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	6.36e-05	0.000265	CcSEcCtD
Lansoprazole—Discomfort—Doxorubicin—testicular cancer	6.32e-05	0.000264	CcSEcCtD
Lansoprazole—Anorexia—Epirubicin—testicular cancer	6.32e-05	0.000264	CcSEcCtD
Lansoprazole—Dyspnoea—Methotrexate—testicular cancer	6.32e-05	0.000264	CcSEcCtD
Lansoprazole—Somnolence—Methotrexate—testicular cancer	6.3e-05	0.000263	CcSEcCtD
Lansoprazole—Dry mouth—Doxorubicin—testicular cancer	6.26e-05	0.000261	CcSEcCtD
Lansoprazole—Dyspepsia—Methotrexate—testicular cancer	6.24e-05	0.00026	CcSEcCtD
Lansoprazole—Hypotension—Epirubicin—testicular cancer	6.2e-05	0.000259	CcSEcCtD
Lansoprazole—Confusional state—Doxorubicin—testicular cancer	6.19e-05	0.000258	CcSEcCtD
Lansoprazole—Decreased appetite—Methotrexate—testicular cancer	6.16e-05	0.000257	CcSEcCtD
Lansoprazole—Oedema—Doxorubicin—testicular cancer	6.14e-05	0.000256	CcSEcCtD
Lansoprazole—Anaphylactic shock—Doxorubicin—testicular cancer	6.14e-05	0.000256	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Methotrexate—testicular cancer	6.12e-05	0.000255	CcSEcCtD
Lansoprazole—Fatigue—Methotrexate—testicular cancer	6.11e-05	0.000255	CcSEcCtD
Lansoprazole—Infection—Doxorubicin—testicular cancer	6.1e-05	0.000254	CcSEcCtD
Lansoprazole—Pain—Methotrexate—testicular cancer	6.06e-05	0.000253	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Epirubicin—testicular cancer	6.04e-05	0.000252	CcSEcCtD
Lansoprazole—Shock—Doxorubicin—testicular cancer	6.04e-05	0.000252	CcSEcCtD
Lansoprazole—Nervous system disorder—Doxorubicin—testicular cancer	6.02e-05	0.000251	CcSEcCtD
Lansoprazole—Thrombocytopenia—Doxorubicin—testicular cancer	6.01e-05	0.000251	CcSEcCtD
Lansoprazole—Insomnia—Epirubicin—testicular cancer	6e-05	0.00025	CcSEcCtD
Lansoprazole—Tachycardia—Doxorubicin—testicular cancer	5.99e-05	0.00025	CcSEcCtD
Lansoprazole—Skin disorder—Doxorubicin—testicular cancer	5.96e-05	0.000249	CcSEcCtD
Lansoprazole—Paraesthesia—Epirubicin—testicular cancer	5.95e-05	0.000249	CcSEcCtD
Lansoprazole—Hyperhidrosis—Doxorubicin—testicular cancer	5.93e-05	0.000248	CcSEcCtD
Lansoprazole—Dyspnoea—Epirubicin—testicular cancer	5.91e-05	0.000247	CcSEcCtD
Lansoprazole—Somnolence—Epirubicin—testicular cancer	5.9e-05	0.000246	CcSEcCtD
Lansoprazole—Anorexia—Doxorubicin—testicular cancer	5.85e-05	0.000244	CcSEcCtD
Lansoprazole—Feeling abnormal—Methotrexate—testicular cancer	5.84e-05	0.000244	CcSEcCtD
Lansoprazole—Dyspepsia—Epirubicin—testicular cancer	5.84e-05	0.000244	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Methotrexate—testicular cancer	5.79e-05	0.000242	CcSEcCtD
Lansoprazole—Decreased appetite—Epirubicin—testicular cancer	5.76e-05	0.000241	CcSEcCtD
Lansoprazole—Hypotension—Doxorubicin—testicular cancer	5.73e-05	0.000239	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Epirubicin—testicular cancer	5.72e-05	0.000239	CcSEcCtD
Lansoprazole—Fatigue—Epirubicin—testicular cancer	5.72e-05	0.000239	CcSEcCtD
Lansoprazole—Pain—Epirubicin—testicular cancer	5.67e-05	0.000237	CcSEcCtD
Lansoprazole—Constipation—Epirubicin—testicular cancer	5.67e-05	0.000237	CcSEcCtD
Lansoprazole—Urticaria—Methotrexate—testicular cancer	5.63e-05	0.000235	CcSEcCtD
Lansoprazole—Abdominal pain—Methotrexate—testicular cancer	5.6e-05	0.000234	CcSEcCtD
Lansoprazole—Body temperature increased—Methotrexate—testicular cancer	5.6e-05	0.000234	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Doxorubicin—testicular cancer	5.59e-05	0.000233	CcSEcCtD
Lansoprazole—Insomnia—Doxorubicin—testicular cancer	5.55e-05	0.000232	CcSEcCtD
Lansoprazole—Paraesthesia—Doxorubicin—testicular cancer	5.51e-05	0.00023	CcSEcCtD
Lansoprazole—Dyspnoea—Doxorubicin—testicular cancer	5.47e-05	0.000228	CcSEcCtD
Lansoprazole—Feeling abnormal—Epirubicin—testicular cancer	5.46e-05	0.000228	CcSEcCtD
Lansoprazole—Somnolence—Doxorubicin—testicular cancer	5.45e-05	0.000228	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Epirubicin—testicular cancer	5.42e-05	0.000226	CcSEcCtD
Lansoprazole—Dyspepsia—Doxorubicin—testicular cancer	5.4e-05	0.000225	CcSEcCtD
Lansoprazole—Decreased appetite—Doxorubicin—testicular cancer	5.33e-05	0.000223	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Doxorubicin—testicular cancer	5.3e-05	0.000221	CcSEcCtD
Lansoprazole—Fatigue—Doxorubicin—testicular cancer	5.29e-05	0.000221	CcSEcCtD
Lansoprazole—Urticaria—Epirubicin—testicular cancer	5.27e-05	0.00022	CcSEcCtD
Lansoprazole—Constipation—Doxorubicin—testicular cancer	5.25e-05	0.000219	CcSEcCtD
Lansoprazole—Pain—Doxorubicin—testicular cancer	5.25e-05	0.000219	CcSEcCtD
Lansoprazole—Body temperature increased—Epirubicin—testicular cancer	5.24e-05	0.000219	CcSEcCtD
Lansoprazole—Abdominal pain—Epirubicin—testicular cancer	5.24e-05	0.000219	CcSEcCtD
Lansoprazole—Hypersensitivity—Methotrexate—testicular cancer	5.22e-05	0.000218	CcSEcCtD
Lansoprazole—Asthenia—Methotrexate—testicular cancer	5.08e-05	0.000212	CcSEcCtD
Lansoprazole—Feeling abnormal—Doxorubicin—testicular cancer	5.06e-05	0.000211	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Doxorubicin—testicular cancer	5.02e-05	0.000209	CcSEcCtD
Lansoprazole—Pruritus—Methotrexate—testicular cancer	5.01e-05	0.000209	CcSEcCtD
Lansoprazole—Hypersensitivity—Epirubicin—testicular cancer	4.89e-05	0.000204	CcSEcCtD
Lansoprazole—Urticaria—Doxorubicin—testicular cancer	4.87e-05	0.000203	CcSEcCtD
Lansoprazole—Abdominal pain—Doxorubicin—testicular cancer	4.85e-05	0.000202	CcSEcCtD
Lansoprazole—Body temperature increased—Doxorubicin—testicular cancer	4.85e-05	0.000202	CcSEcCtD
Lansoprazole—Diarrhoea—Methotrexate—testicular cancer	4.85e-05	0.000202	CcSEcCtD
Lansoprazole—Asthenia—Epirubicin—testicular cancer	4.76e-05	0.000199	CcSEcCtD
Lansoprazole—Pruritus—Epirubicin—testicular cancer	4.69e-05	0.000196	CcSEcCtD
Lansoprazole—Dizziness—Methotrexate—testicular cancer	4.69e-05	0.000196	CcSEcCtD
Lansoprazole—Diarrhoea—Epirubicin—testicular cancer	4.54e-05	0.000189	CcSEcCtD
Lansoprazole—Hypersensitivity—Doxorubicin—testicular cancer	4.52e-05	0.000189	CcSEcCtD
Lansoprazole—Vomiting—Methotrexate—testicular cancer	4.51e-05	0.000188	CcSEcCtD
Lansoprazole—Rash—Methotrexate—testicular cancer	4.47e-05	0.000186	CcSEcCtD
Lansoprazole—Dermatitis—Methotrexate—testicular cancer	4.46e-05	0.000186	CcSEcCtD
Lansoprazole—Headache—Methotrexate—testicular cancer	4.44e-05	0.000185	CcSEcCtD
Lansoprazole—Asthenia—Doxorubicin—testicular cancer	4.4e-05	0.000184	CcSEcCtD
Lansoprazole—Dizziness—Epirubicin—testicular cancer	4.38e-05	0.000183	CcSEcCtD
Lansoprazole—Pruritus—Doxorubicin—testicular cancer	4.34e-05	0.000181	CcSEcCtD
Lansoprazole—Vomiting—Epirubicin—testicular cancer	4.22e-05	0.000176	CcSEcCtD
Lansoprazole—Nausea—Methotrexate—testicular cancer	4.21e-05	0.000176	CcSEcCtD
Lansoprazole—Diarrhoea—Doxorubicin—testicular cancer	4.2e-05	0.000175	CcSEcCtD
Lansoprazole—Rash—Epirubicin—testicular cancer	4.18e-05	0.000174	CcSEcCtD
Lansoprazole—Dermatitis—Epirubicin—testicular cancer	4.18e-05	0.000174	CcSEcCtD
Lansoprazole—Headache—Epirubicin—testicular cancer	4.15e-05	0.000173	CcSEcCtD
Lansoprazole—Dizziness—Doxorubicin—testicular cancer	4.06e-05	0.000169	CcSEcCtD
Lansoprazole—Nausea—Epirubicin—testicular cancer	3.94e-05	0.000164	CcSEcCtD
Lansoprazole—Vomiting—Doxorubicin—testicular cancer	3.9e-05	0.000163	CcSEcCtD
Lansoprazole—Rash—Doxorubicin—testicular cancer	3.87e-05	0.000161	CcSEcCtD
Lansoprazole—Dermatitis—Doxorubicin—testicular cancer	3.86e-05	0.000161	CcSEcCtD
Lansoprazole—Headache—Doxorubicin—testicular cancer	3.84e-05	0.00016	CcSEcCtD
Lansoprazole—Nausea—Doxorubicin—testicular cancer	3.64e-05	0.000152	CcSEcCtD
